The technology is based on CAR-T cells containing suicide genes that accumulate better in the cancer tissue and have high survival / proliferation ability and sustainability and was developed by Konji TAMADA of Yamaguchi University (WO / 2016/05 62228).
Noile-Immune Biotech news release, July 4, 2018
Tokyo’s Noile-Immune Biotech to start CART cell therapy for solid cancer clinical trials within 2 years